Athira Pharma Inc (ATHA) Stock Price, Quote & News

Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 620 8501

Website: www.athira.com

Address:

18706 North Creek Parkway, Suite 104, Bothell, United States

11thestate Jun. 16 at 11:30 AM

Don’t forget that there is also an important class action case to watch for $ATHA. We have every detail, including how investors can get paid. #AthiraPharma #ATHA https://11th.com/cases/athira-ipo-spo-settlement

0 · Reply

Alice_in_Dollarland Jun. 10 at 1:27 PM

$ELTP Make sure you're tagging other tickers. Upwards action with big rewards. I don't own many OTC stocks (I only take on a couple at a time), but I know certain investors, such as those holding shares in $KTTA $ATHA $TEVA might want a peak at this. Pharmaceutical company specializing in a broad range of generic medications, including Oxycodone, Percocet, and Vyvanse. Next earnings report set for the end of THIS month and will show revenue for the launch of these new releases. New working facility HERE in the states. $RDAR

0 · Reply

11thestate Jun. 5 at 10:54 PM

Don’t forget that if you held $ATHA, there’s a significant settlement you can also claim. Consider it the dividend #Athira never paid. https://11th.com/cases/athira-ipo-spo-settlement

0 · Reply

no_mountain_too_high Jun. 5 at 7:59 PM

$ATHA - Always interesting when you see love in Darkpool for this stock - lets see what will happen in the future

0 · Reply

Bgirl_smirk Jun. 5 at 3:22 PM

$ATHA come on get it done

0 · Reply

Bgirl_smirk Jun. 5 at 2:18 PM

$ATHA come on

0 · Reply

Gconstance88 Jun. 4 at 11:40 PM

$ATHA solid steady climb. Lets get it tmw.

0 · Reply

Gconstance88 Jun. 4 at 6:17 PM

$ATHA why is it so difficult to break into .34 lets go ! Break that and we are off to the races

0 · Reply

Bgirl_smirk Jun. 4 at 4:48 PM

$ATHA I know my shit 😂🙏

0 · Reply

AHazyBite Jun. 4 at 3:57 PM

$ATHA what’s going on

0 · Reply

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025, 4:05 PM EDT - 5 weeks ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 3 months ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Jan 7, 2025, 5:15 PM EST - 5 months ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Dec 6, 2024, 5:30 PM EST - 6 months ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Nov 7, 2024, 4:05 PM EST - 7 months ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Sep 17, 2024, 11:59 AM EDT - 9 months ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 9:00 AM EDT - 9 months ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 4, 2024, 8:48 AM EDT - 10 months ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 3, 2024, 4:13 PM EDT - 10 months ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:01 PM EDT - 10 months ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Aug 1, 2024, 4:05 PM EDT - 11 months ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Jul 31, 2024, 8:05 AM EDT - 11 months ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024, 5:00 PM EDT - 1 year ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Conferences

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Mar 8, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Feb 22, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 8, 2024, 4:02 PM EST - 1 year ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Jan 8, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 3, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Dec 12, 2023, 7:00 AM EST - 1 year ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Nov 29, 2023, 7:00 AM EST - 1 year ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 15, 2023, 8:15 AM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 8, 2023, 7:00 AM EST - 1 year ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Oct 5, 2023, 4:30 PM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Sep 19, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

May 22, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 8, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Apr 25, 2023, 4:01 PM EDT - 2 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Mar 28, 2023, 1:00 AM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 23, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 6, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Feb 1, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Jan 31, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 5, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2023 Pipeline Outlook

Dec 21, 2022, 7:00 AM EST - 2 years ago

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Dec 5, 2022, 7:30 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Nov 29, 2022, 11:00 AM EST - 2 years ago

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

Nov 28, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Nov 21, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

11thestate Jun. 16 at 11:30 AM

0 · Reply

Alice_in_Dollarland Jun. 10 at 1:27 PM

0 · Reply

11thestate Jun. 5 at 10:54 PM

Don’t forget that if you held $ATHA, there’s a significant settlement you can also claim. Consider it the dividend #Athira never paid. https://11th.com/cases/athira-ipo-spo-settlement

0 · Reply

no_mountain_too_high Jun. 5 at 7:59 PM

$ATHA - Always interesting when you see love in Darkpool for this stock - lets see what will happen in the future

0 · Reply

Bgirl_smirk Jun. 5 at 3:22 PM

$ATHA come on get it done

0 · Reply

Bgirl_smirk Jun. 5 at 2:18 PM

$ATHA come on

0 · Reply

Gconstance88 Jun. 4 at 11:40 PM

$ATHA solid steady climb. Lets get it tmw.

0 · Reply

Gconstance88 Jun. 4 at 6:17 PM

$ATHA why is it so difficult to break into .34 lets go ! Break that and we are off to the races

0 · Reply

Bgirl_smirk Jun. 4 at 4:48 PM

$ATHA I know my shit 😂🙏

0 · Reply

AHazyBite Jun. 4 at 3:57 PM

$ATHA what’s going on

0 · Reply

Bgirl_smirk Jun. 4 at 3:09 PM

$ATHA same no investors wants to loose money

0 · Reply

Zinvest Jun. 4 at 2:37 PM

$ATHA Good morning! 😃

1 · Reply

Bgirl_smirk Jun. 4 at 2:12 PM

$UOKA profits profits to $ATHA

0 · Reply

Bgirl_smirk Jun. 4 at 11:03 AM

$ATHA took the dip

0 · Reply

Bgirl_smirk Jun. 4 at 6:36 AM

$ATHA adding dips today starter

0 · Reply

beppels Jun. 4 at 6:33 AM

$BAOS BEPPELS WL 04.06.: - $BAOS, ah runner, 900 k float, sympathy to supernova $MCTR which was a tenbagger yesterday! ✅ - $UOKA, 600 k float, China play, compliance news due any day! ✅ - $ATHA, always spikes from 0.3 $, big cash, low dilution risk! ✅ - $SGMT, ah runner on big news, held all gains in overnite continuation play! ✅ China mania could be back after MCTR and Trump talking with XI on Friday, watch for volume at wafu, dxf, ambo, tirx, sntg! 👀 🔥 👀

0 · Reply

Gconstance88 Jun. 4 at 12:25 AM

$ATHA this board went to sleep or what happened... everyone left

0 · Reply

pakman197 Jun. 3 at 6:35 PM

$ATHA I almost had the URGE to not buy this.... due to some shit post this am. People really need to learn how to read a chart. This thing is going to go big! I knew that volume was too big this am (and crossing the 50 dma)..... A lot more coming here!!

0 · Reply

PLATINUM_TRADES Jun. 3 at 2:58 PM

$ATHA $.37 high this premarket early for a nice start to June... Watching if it sets up again⚠️

0 · Reply

RunnerSignals Jun. 3 at 2:06 PM

Volume Surge Watch Big volume moves today! $REVB and $RSLS popping with massive trades $SISI and $ATHA also seeing unusual action

0 · Reply

urgetosurge Jun. 3 at 11:27 AM

$ATHA looks like just another share selling sink hole here. Last post..

0 · Reply

urgetosurge Jun. 3 at 11:02 AM

$ATHA 8k filed yesterday. Reverse split approved. Explains the pre volume.

0 · Reply

Market Cap	11.87M
Revenue (ttm)	0.00
Net Income (ttm)	-96.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	171,400
Avg Vol	665,672
Day's Range	N/A - N/A
Shares Out	39.04M
Stochastic %K	34%
Beta	3.03
Analysts	Hold
Price Target	$7.60